+Compare
BLFS
Stock ticker:
NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
1.01B

BLFS BioLife Solutions Forecast, Technical & Fundamental Analysis

a manufacturer of proprietary and generic bio preservation media products for cells, tissues and organs

GET INTRADAY SIGNALS
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for BLFS with price predictions
08:00 PM EDT Jun 01, 2023

BLFS in upward trend: 10-day moving average crossed above 50-day moving average on May 22, 2023

The 10-day moving average for BLFS crossed bullishly above the 50-day moving average on May 22, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 09, 2023. You may want to consider a long position or call options on BLFS as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for BLFS just turned positive on May 05, 2023. Looking at past instances where BLFS's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .

BLFS moved above its 50-day moving average on May 16, 2023 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BLFS advanced for three days, in of 330 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BLFS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BLFS broke above its upper Bollinger Band on May 16, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for BLFS entered a downward trend on May 16, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BLFS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.815) is normal, around the industry mean (25.286). P/E Ratio (238.095) is within average values for comparable stocks, (143.072). Projected Growth (PEG Ratio) (15.094) is also within normal values, averaging (5.656). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (6.072) is also within normal values, averaging (53.674).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Intuitive Surgical (NASDAQ:ISRG), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW), IQVIA Holdings (NYSE:IQV), Illumina (NASDAQ:ILMN), Align Technology (NASDAQ:ALGN), Exact Sciences Corp (NASDAQ:EXAS), Guardant Health (NASDAQ:GH).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 6.42B. The market cap for tickers in the group ranges from 27 to 3.82T. MKYSF holds the highest valuation in this group at 3.82T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was 1%. For the same Industry, the average monthly price growth was 0%, and the average quarterly price growth was 22%. RSHUF experienced the highest price growth at 158%, while SQIDF experienced the biggest fall at -49%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was 23%. For the same stocks of the Industry, the average monthly volume growth was 14% and the average quarterly volume growth was -77%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 69
Price Growth Rating: 62
SMR Rating: 83
Profit Risk Rating: 85
Seasonality Score: 14 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

BLFS is expected to report earnings to fall 44.28% to -17 cents per share on August 10

BioLife Solutions BLFS Stock Earnings Reports
Q2'23
Est.
$-0.18
Q1'23
Missed
by $0.11
Q4'22
Missed
by $0.99
Q3'22
Missed
by $0.07
Q2'22
Missed
by $1.50
The last earnings report on May 10 showed earnings per share of -31 cents, missing the estimate of -20 cents. With 305.46K shares outstanding, the current market capitalization sits at 1.01B.
A.I. Advisor
published General Information

General Information

a manufacturer of proprietary and generic bio preservation media products for cells, tissues and organs

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
3303 Monte Villa Parkway
Phone
+1 425 402-1400
Employees
467
Web
https://www.biolifesolutions.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HVOVX23.480.48
+2.09%
Hartford Quality Value R6
EATVX34.550.66
+1.95%
Eaton Vance Tx-Mgd Value A
ARTGX19.310.28
+1.47%
Artisan Global Value Investor
FGIGX34.130.41
+1.22%
American Funds Intl Gr and Inc529-F-3
GPMCX12.510.13
+1.05%
Grandeur Peak Global Micro Cap Instl

BLFS and

Correlation & Price change

A.I.dvisor indicates that over the last year, BLFS has been loosely correlated with LUNG. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if BLFS jumps, then LUNG could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BLFS
1D Price
Change %
BLFS100%
+0.43%
LUNG - BLFS
57%
Loosely correlated
+5.27%
CSTL - BLFS
56%
Loosely correlated
+7.98%
PACB - BLFS
55%
Loosely correlated
+4.90%
IQV - BLFS
55%
Loosely correlated
+1.21%
ICLR - BLFS
55%
Loosely correlated
+2.59%
More

Groups containing BLFS

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BLFS
1D Price
Change %
BLFS100%
+0.43%
cells
(undefined stocks)
95%
Closely correlated
+2.29%
tissues
(undefined stocks)
90%
Closely correlated
-0.18%
medical research
(undefined stocks)
60%
Loosely correlated
+1.67%
biological
(undefined stocks)
59%
Loosely correlated
+1.95%
medical service
(undefined stocks)
59%
Loosely correlated
+1.57%
More